ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel

ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing and anion channel activity conferred by the major cystic fibrosis–causing mutation, F508del, in in vitro studies. Clinically, the improvement in lung function after ORKAMBI...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmacology Vol. 96; no. 4; pp. 515 - 525
Main Authors Wu, Yu-Sheng, Jiang, Janet, Ahmadi, Saumel, Lew, Alexandria, Laselva, Onofrio, Xia, Sunny, Bartlett, Claire, Ip, Wan, Wellhauser, Leigh, Ouyang, Hong, Gonska, Tanja, Moraes, Theo J., Bear, Christine E.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.10.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing and anion channel activity conferred by the major cystic fibrosis–causing mutation, F508del, in in vitro studies. Clinically, the improvement in lung function after ORKAMBI treatment is modest and variable, prompting the search for complementary interventions. As our previous work identified a positive effect of arginine-dependent nitric oxide signaling on residual F508del-Cftr function in murine intestinal epithelium, we were prompted to determine whether strategies aimed at increasing arginine would enhance F508del–cystic fibrosis transmembrane conductance regulator (CFTR) channel activity in patient-derived airway epithelia. Now, we show that the addition of arginine together with inhibition of intracellular arginase activity increased cytosolic nitric oxide and enhanced the rescue effect of ORKAMBI on F508del-CFTR–mediated chloride conductance at the cell surface of patient-derived bronchial and nasal epithelial cultures. Interestingly, arginine addition plus arginase inhibition also enhanced ORKAMBI-mediated increases in ciliary beat frequency and mucociliary movement, two in vitro CF phenotypes that are downstream of the channel defect. This work suggests that strategies to manipulate the arginine–nitric oxide pathway in combination with CFTR modulators may lead to improved clinical outcomes. These proof-of-concept studies highlight the potential to boost the response to cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators, lumacaftor and ivacaftor, in patient-derived airway tissues expressing the major CF-causing mutant, F508del-CFTR, by enhancing other regulatory pathways. In this case, we observed enhancement of pharmacologically rescued F508del-CFTR by arginine-dependent, nitric oxide signaling through inhibition of endogenous arginase activity.
AbstractList ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing and anion channel activity conferred by the major cystic fibrosis–causing mutation, F508del, in in vitro studies. Clinically, the improvement in lung function after ORKAMBI treatment is modest and variable, prompting the search for complementary interventions. As our previous work identified a positive effect of arginine-dependent nitric oxide signaling on residual F508del-Cftr function in murine intestinal epithelium, we were prompted to determine whether strategies aimed at increasing arginine would enhance F508del–cystic fibrosis transmembrane conductance regulator (CFTR) channel activity in patient-derived airway epithelia. Now, we show that the addition of arginine together with inhibition of intracellular arginase activity increased cytosolic nitric oxide and enhanced the rescue effect of ORKAMBI on F508del-CFTR–mediated chloride conductance at the cell surface of patient-derived bronchial and nasal epithelial cultures. Interestingly, arginine addition plus arginase inhibition also enhanced ORKAMBI-mediated increases in ciliary beat frequency and mucociliary movement, two in vitro CF phenotypes that are downstream of the channel defect. This work suggests that strategies to manipulate the arginine–nitric oxide pathway in combination with CFTR modulators may lead to improved clinical outcomes. These proof-of-concept studies highlight the potential to boost the response to cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators, lumacaftor and ivacaftor, in patient-derived airway tissues expressing the major CF-causing mutant, F508del-CFTR, by enhancing other regulatory pathways. In this case, we observed enhancement of pharmacologically rescued F508del-CFTR by arginine-dependent, nitric oxide signaling through inhibition of endogenous arginase activity.
ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing and anion channel activity conferred by the major cystic fibrosis-causing mutation, F508del, in in vitro studies. Clinically, the improvement in lung function after ORKAMBI treatment is modest and variable, prompting the search for complementary interventions. As our previous work identified a positive effect of arginine-dependent nitric oxide signaling on residual F508del-Cftr function in murine intestinal epithelium, we were prompted to determine whether strategies aimed at increasing arginine would enhance F508del-cystic fibrosis transmembrane conductance regulator (CFTR) channel activity in patient-derived airway epithelia. Now, we show that the addition of arginine together with inhibition of intracellular arginase activity increased cytosolic nitric oxide and enhanced the rescue effect of ORKAMBI on F508del-CFTR-mediated chloride conductance at the cell surface of patient-derived bronchial and nasal epithelial cultures. Interestingly, arginine addition plus arginase inhibition also enhanced ORKAMBI-mediated increases in ciliary beat frequency and mucociliary movement, two in vitro CF phenotypes that are downstream of the channel defect. This work suggests that strategies to manipulate the arginine-nitric oxide pathway in combination with CFTR modulators may lead to improved clinical outcomes. SIGNIFICANCE STATEMENT: These proof-of-concept studies highlight the potential to boost the response to cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators, lumacaftor and ivacaftor, in patient-derived airway tissues expressing the major CF-causing mutant, F508del-CFTR, by enhancing other regulatory pathways. In this case, we observed enhancement of pharmacologically rescued F508del-CFTR by arginine-dependent, nitric oxide signaling through inhibition of endogenous arginase activity.
Author Ouyang, Hong
Ahmadi, Saumel
Wellhauser, Leigh
Bear, Christine E.
Gonska, Tanja
Ip, Wan
Wu, Yu-Sheng
Xia, Sunny
Moraes, Theo J.
Laselva, Onofrio
Bartlett, Claire
Lew, Alexandria
Jiang, Janet
Author_xml – sequence: 1
  givenname: Yu-Sheng
  surname: Wu
  fullname: Wu, Yu-Sheng
– sequence: 2
  givenname: Janet
  surname: Jiang
  fullname: Jiang, Janet
– sequence: 3
  givenname: Saumel
  surname: Ahmadi
  fullname: Ahmadi, Saumel
– sequence: 4
  givenname: Alexandria
  surname: Lew
  fullname: Lew, Alexandria
– sequence: 5
  givenname: Onofrio
  surname: Laselva
  fullname: Laselva, Onofrio
– sequence: 6
  givenname: Sunny
  surname: Xia
  fullname: Xia, Sunny
– sequence: 7
  givenname: Claire
  surname: Bartlett
  fullname: Bartlett, Claire
– sequence: 8
  givenname: Wan
  surname: Ip
  fullname: Ip, Wan
– sequence: 9
  givenname: Leigh
  surname: Wellhauser
  fullname: Wellhauser, Leigh
– sequence: 10
  givenname: Hong
  surname: Ouyang
  fullname: Ouyang, Hong
– sequence: 11
  givenname: Tanja
  surname: Gonska
  fullname: Gonska, Tanja
– sequence: 12
  givenname: Theo J.
  surname: Moraes
  fullname: Moraes, Theo J.
– sequence: 13
  givenname: Christine E.
  surname: Bear
  fullname: Bear, Christine E.
  email: bear@sickkids.ca
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31427400$$D View this record in MEDLINE/PubMed
BookMark eNp1UUFv0zAYNWiIdYMrR-Qjh2XYjpM0x63aoGKlqGwSt8ixv7YfJHaxHUT_PQ4ZXBCyLH-233t-n98ZObHOAiGvOLvkXMi3vetSUadZcZk_JTNeCJ4xzvkJmTEmymxeF19OyVkIXxnjspiz5-Q051JUkrHZE7LefLhaXS-zFRhUEQzdQNADULelq0E7jR0qf6SLDpRXVgNFSxfHEFHTW2y9CxjoJ4_9CErUA3oV3UgYujh4CHQZ6I3dj1RD2yO98ju0aIE-HKL6BhfTgQpAl3aPLUZ09oIqa5Kq6924Hb18xOjTk-ufaIB-xp1VHdodjY7GPfxj6D5ZDT30bVrTrbNm0PG3-w3shm50SBfJk4XuBXm2VV2Al4_rOXm4vblfvM_u1u-Wi6u7TMuCxSwvdcHKvBKiYLlQZi4Lw7fM5Lrairpmklegcm2UkQLKVksNJYhc51UaRaXzc_Jm0j14932AEJseg4auSw7dEBoh6qRTCjlP0MsJqlM3wcO2OUwf3HDWjKk3KfVU1M2UeiK8ftQe2h7MX_ifmBNgPgEgdfgDwTdBI4yRoAcdG-Pwf9q_AM0vwO4
CitedBy_id crossref_primary_10_1016_j_ebiom_2021_103660
crossref_primary_10_1016_j_phymed_2024_155755
crossref_primary_10_1016_j_jcf_2021_04_013
crossref_primary_10_1152_ajpcell_00356_2022
crossref_primary_10_7759_cureus_12251
crossref_primary_10_3390_jpm12081321
crossref_primary_10_3390_ijms22094448
crossref_primary_10_3390_ijms231911396
crossref_primary_10_1002_adfm_202006116
crossref_primary_10_1016_j_pupt_2021_102098
crossref_primary_10_3389_fphar_2021_627503
crossref_primary_10_4049_jimmunol_2100424
crossref_primary_10_1183_13993003_02774_2020
crossref_primary_10_3390_jcm9123802
crossref_primary_10_3390_jpm11050421
crossref_primary_10_1016_j_jcf_2019_12_001
crossref_primary_10_1016_j_omtm_2020_05_002
crossref_primary_10_1038_s41467_021_26764_0
crossref_primary_10_3390_cells10123419
crossref_primary_10_1183_23120541_00365_2021
crossref_primary_10_3390_jor1040022
crossref_primary_10_1038_s41598_022_05446_x
crossref_primary_10_1080_19491034_2022_2069071
crossref_primary_10_1183_13993003_00205_2020
crossref_primary_10_3390_biom10020334
crossref_primary_10_3390_ijms23042136
crossref_primary_10_3390_jpm10040209
crossref_primary_10_3390_jpm11040301
crossref_primary_10_4331_wjbc_v11_i2_30
crossref_primary_10_1080_17460441_2020_1750592
crossref_primary_10_1016_j_stemcr_2021_09_020
crossref_primary_10_3390_ijms21155291
crossref_primary_10_1016_j_jcf_2020_07_015
crossref_primary_10_1186_s12931_024_02889_w
crossref_primary_10_3390_jpm10020040
Cites_doi 10.1038/s41598-017-07504-1
10.1073/pnas.1105787108
10.1016/j.jcf.2013.06.008
10.7554/eLife.37963
10.1124/mol.118.111799
10.1136/thx.2011.159491
10.1164/rccm.200502-253OC
10.1164/ajrccm.162.6.2003106
10.1177/0194599816640219
10.1172/jci.insight.99385
10.1113/jphysiol.2004.068171
10.1073/pnas.1215982110
10.1053/j.gastro.2003.10.049
10.2174/138161212799315911
10.1073/pnas.0904709106
10.1038/s41525-017-0015-6
10.1177/1087057115605834
10.1183/09031936.04.00086104
10.1016/j.abb.2011.04.003
10.1073/pnas.0706974104
10.1056/NEJMoa1409547
10.1016/j.jpeds.2013.02.042
10.1089/hum.2017.201
10.1152/japplphysiol.00167.2014
10.3389/fphar.2018.00719
10.1126/scitranslmed.aad8278
10.1183/09031936.00103907
10.3121/cmr.2016.1320
10.1164/ajrccm.165.7.2105032
10.1002/ppul.23553
10.1074/jbc.M112.393637
10.1183/13993003.congress-2018.PA3415
10.1186/s40425-017-0308-4
10.1358/dot.2016.52.4.2467205
10.1152/ajpcell.00384.2011
10.1074/jbc.M116.762633
10.1016/j.jcf.2012.12.008
10.1016/j.jcf.2014.10.006
10.1183/09031936.99.13111499
10.1016/S0092-8674(00)81724-9
10.3791/50646.
10.1016/S2213-2600(17)30215-1
10.1016/S0954-6111(99)90158-0
10.1080/23808993.2016.1175299
10.1038/mtm.2015.34
10.1016/S0954-6111(08)80058-3
10.1002/prot.25496
10.1016/j.jcf.2011.12.005
10.1016/S0021-9258(19)49254-5
ContentType Journal Article
Copyright 2019 American Society for Pharmacology and Experimental Therapeutics
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.
Copyright_xml – notice: 2019 American Society for Pharmacology and Experimental Therapeutics
– notice: Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1124/mol.119.117143
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0111
EndPage 525
ExternalDocumentID 10_1124_mol_119_117143
31427400
S0026895X24009556
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: CIHR
  grantid: GPG-102171
– fundername: CIHR
  grantid: MOP-125855
GroupedDBID ---
-~X
.55
.GJ
0R~
123
18M
2WC
34G
39C
4.4
53G
5RE
5VS
AAJMC
ABCQX
ABJNI
ABSQV
ACGFO
ACGFS
ADBBV
ADCOW
AENEX
AERNN
AFFNX
AFHIN
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AYCSE
BAWUL
BTFSW
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HH5
HZ~
IH2
INIJC
K-O
KQ8
L7B
LSO
MVM
N9A
O9-
OK1
P2P
R.V
R0Z
RHF
RHI
RPT
TR2
UQL
W8F
WOQ
X7M
XOL
YBU
YHG
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c450t-36c50637225032ad845d1f0d3c7f2990417ea3cdad42e6bc4ce6e23c3737357c3
ISSN 0026-895X
IngestDate Fri Oct 25 06:12:28 EDT 2024
Fri Dec 06 02:24:27 EST 2024
Sat Sep 28 08:32:13 EDT 2024
Wed Dec 04 16:49:18 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords ACC
NO
CF
CBF
ABH
MCCV
DAF-FM
iNOS
FLIPR
HBSS
WT
ALI
CFTR
FSK
Language English
License Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c450t-36c50637225032ad845d1f0d3c7f2990417ea3cdad42e6bc4ce6e23c3737357c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://molpharm.aspetjournals.org/content/molpharm/96/4/515.full.pdf
PMID 31427400
PQID 2292996248
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_2292996248
crossref_primary_10_1124_mol_119_117143
pubmed_primary_31427400
elsevier_sciencedirect_doi_10_1124_mol_119_117143
PublicationCentury 2000
PublicationDate 2019-10-01
PublicationDateYYYYMMDD 2019-10-01
PublicationDate_xml – month: 10
  year: 2019
  text: 2019-10-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmacology
PublicationTitleAlternate Mol Pharmacol
PublicationYear 2019
Publisher Elsevier Inc
Publisher_xml – sequence: 0
  name: Elsevier Inc
References Brewington, Filbrandt, LaRosa III, Moncivaiz, Ostmann, Strecker, Clancy (bib4) 2018; 3
Treharne, Crawford, Xu, Chen, Best, Schulte, Gruenert, Wilson, Sheppard, Kunzelmann (bib43) 2008; 283
Laselva, Marzaro, Vaccarin, Lampronti, Tamanini, Lippi, Gambari, Cabrini, Bear, Chilin (bib27) 2018; 9
Kerley, Kilbride, Greally, Elnazir (bib26) 2016; 14
Ostedgaard, Rogers, Dong, Randak, Vermeer, Rokhlina, Karp, Welsh (bib34) 2007; 104
Grasemann, Ratjen (bib21) 2012; 18
Cao, Ouyang, Grasemann, Bartlett, Du, Duan, Shi, Estrada, Seigel, Coates (bib5) 2018; 29
Ratjen, Gärtig, Wiesemann, Grasemann (bib36) 1999; 93
Beekman (bib3) 2016; 51
Van Goor, Yu, Burton, Hoffman (bib47) 2014; 13
Zhang, Zhang, Zhang, Strokes, Naren (bib51) 2016; 52
Molinski, Shahani, Subramanian, MacKinnon, Woollard, Laforet, Laselva, Morayniss, Bear, Windemuth (bib32) 2018; 86
Cholon, Esther Jr, Gentzsch (bib9) 2016; 1
Grasemann, Pencharz (bib20) 2013; 163
van den Berg, Kurhade, Lunev, van Faassen, Bos, Zuidhof, Groves, Kema, Dömling, Meurs (bib44) 2018; 197
Galietta, Musante, Romio, Caruso, Fantasia, Gazzolo, Romano, Sacco, Rossi, Varesio (bib14) 1998; 275
Laselva, Molinski, Casavola, Bear (bib28) 2018; 93
Van Goor, Hadida, Grootenhuis, Burton, Cao, Neuberger, Turnbull, Singh, Joubran, Hazlewood (bib45) 2009; 106
Sutto, Conner, Salathe (bib41) 2004; 560
Jaecklin, Duerr, Huang, Rafii, Bear, Ratjen, Pencharz, Kavanagh, Mall, Grasemann (bib24) 2014; 117
Steggerda, Bennett, Chen, Emberley, Huang, Janes, Li, MacKinnon, Makkouk, Marguier (bib40) 2017; 5
Dekkers, Berkers, Kruisselbrink, Vonk, de Jonge, Janssens, Bronsveld, van de Graaf, Nieuwenhuis, Houwen (bib11) 2016; 8
Grasemann, Gärtig, Wiesemann, Teschler, Konietzko, Ratjen (bib17) 1999; 13
Grasemann, Grasemann, Kurtz, Tietze-Schillings, Vester, Ratjen (bib18) 2005; 25
Pranke, Hatton, Simonin, Jais, Le Pimpec-Barthes, Carsin, Bonnette, Fayon, Stremler-Le Bel, Grenet (bib35) 2017; 7
Matsui, Grubb, Tarran, Randell, Gatzy, Davis, Boucher (bib30) 1998; 95
Devalia, Sapsford, Wells, Richman, Davies (bib12) 1990; 84
de Courcey, Zholos, Atherton-Watson, Williams, Canning, Danahay, Elborn, Ennis (bib10) 2012; 303
Molinski, Ahmadi, Hung, Bear (bib31) 2015; 20
Grasemann, Ratjen, Schnabel, Reutershahn, Vester, Grasemann (bib16) 2008; 31
Chen, Lemieux, Wong (bib7) 2016; 155
Van Goor, Hadida, Grootenhuis, Burton, Stack, Straley, Decker, Miller, McCartney, Olson (bib46) 2011; 108
Ahmadi, Xia, Wu, Di Paola, Kissoon, Luk, Lin, Du, Rommens, Bear (bib2) 2018; 7
Grasemann, Knauer, Büscher, Hübner, Drazen, Ratjen (bib19) 2000; 162
Yu, Burton, Huang, Worley, Cao, Johnson Jr, Urrutia, Joubran, Seepersaud, Sussky (bib50) 2012; 11
Ahmadi, Bozoky, Di Paola, Xia, Li, Wong, Wellhauser, Molinski, Ip, Ouyang (bib1) 2017; 2
Wirschell, Yamamoto, Alford, Gokhale, Gaillard, Sale (bib49) 2011; 510
Eckford, Li, Ramjeesingh, Bear (bib13) 2012; 287
Jih, Hwang (bib25) 2013; 110
Chin, Yang, Miles, Eckford, Molinski, Wallace, Bear (bib8) 2017; 292
Mall, Kreda, Mengos, Jensen, Hirtz, Seydewitz, Yankaskas, Kunzelmann, Riordan, Boucher (bib29) 2004; 126
Ratjen, Hug, Marigowda, Tian, Huang, Stanojevic, Milla, Robinson, Waltz, Davies (bib37) 2017; 5
Gräber, Dopfer, Naehrlich, Gyulumyan, Scheuermann, Hirtz, Wege, Mairbaeurl, Dorda, Hyde (bib15) 2018; 52
Grasemann, Schwiertz, Matthiesen, Racké, Ratjen (bib22) 2005; 172
Müller, Brighton, Carson, Fischer II, Jaspers (bib33) 2013
Shah (bib38) 2011; 66
Cao, Ouyang, Ip, Du, Duan, Avolio, Wu, Duan, Yeger, Bear (bib6) 2015; 2
Wainwright, Elborn, Ramsey, Marigowda, Huang, Cipolli, Colombo, Davies, De Boeck, Flume (bib48) 2015; 373
Snyder, McPherson, Hunt, Johnson, Stamler, Gaston (bib39) 2002; 165
Grasemann, Tullis, Ratjen (bib23) 2013; 12
Taylor-Cousar, Wiley, Felton, St Clair, Jones, Curran-Everett, Poch, Nichols, Solomon, Saavedra (bib42) 2015; 14
Galietta (2019091712290063000_96.4.515.14) 1998; 275
2019091712290063000_96.4.515.7
2019091712290063000_96.4.515.21
2019091712290063000_96.4.515.8
2019091712290063000_96.4.515.22
2019091712290063000_96.4.515.9
2019091712290063000_96.4.515.25
Treharne (2019091712290063000_96.4.515.43) 2008; 283
2019091712290063000_96.4.515.26
2019091712290063000_96.4.515.23
2019091712290063000_96.4.515.24
2019091712290063000_96.4.515.29
2019091712290063000_96.4.515.28
Cao (2019091712290063000_96.4.515.6) 2015; 2
Cao (2019091712290063000_96.4.515.5) 2018; 29
Ratjen (2019091712290063000_96.4.515.37) 2017; 5
Beekman (2019091712290063000_96.4.515.3) 2016; 51
Molinski (2019091712290063000_96.4.515.32) 2018; 86
2019091712290063000_96.4.515.33
2019091712290063000_96.4.515.30
2019091712290063000_96.4.515.31
2019091712290063000_96.4.515.36
2019091712290063000_96.4.515.34
Brewington (2019091712290063000_96.4.515.4) 2018; 3
2019091712290063000_96.4.515.35
van den Berg (2019091712290063000_96.4.515.44) 2018; 197
2019091712290063000_96.4.515.38
2019091712290063000_96.4.515.39
Grasemann (2019091712290063000_96.4.515.20) 2013; 163
Ahmadi (2019091712290063000_96.4.515.2) 2018; 7
Zhang (2019091712290063000_96.4.515.51) 2016; 52
2019091712290063000_96.4.515.40
2019091712290063000_96.4.515.41
2019091712290063000_96.4.515.42
2019091712290063000_96.4.515.47
2019091712290063000_96.4.515.48
2019091712290063000_96.4.515.45
Ahmadi (2019091712290063000_96.4.515.1) 2017; 2
2019091712290063000_96.4.515.46
2019091712290063000_96.4.515.49
2019091712290063000_96.4.515.50
2019091712290063000_96.4.515.10
2019091712290063000_96.4.515.11
Laselva (2019091712290063000_96.4.515.27) 2018; 9
2019091712290063000_96.4.515.15
2019091712290063000_96.4.515.12
2019091712290063000_96.4.515.13
2019091712290063000_96.4.515.18
2019091712290063000_96.4.515.19
2019091712290063000_96.4.515.16
2019091712290063000_96.4.515.17
References_xml – volume: 52
  year: 2018
  ident: bib15
  article-title: Effects of lumacaftor-ivacaftor therapy on CFTR function in Phe508del homozygous patients with cystic fibrosis
  publication-title: Eur Respir J
  contributor:
    fullname: Hyde
– volume: 165
  start-page: 922
  year: 2002
  end-page: 926
  ident: bib39
  article-title: Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: Gaston
– volume: 11
  start-page: 237
  year: 2012
  end-page: 245
  ident: bib50
  article-title: Ivacaftor potentiation of multiple CFTR channels with gating mutations
  publication-title: J Cyst Fibros
  contributor:
    fullname: Sussky
– volume: 2
  start-page: 15034
  year: 2015
  ident: bib6
  article-title: Testing gene therapy vectors in human primary nasal epithelial cultures
  publication-title: Mol Ther Methods Clin Dev
  contributor:
    fullname: Bear
– volume: 7
  start-page: 7375
  year: 2017
  ident: bib35
  article-title: Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators
  publication-title: Sci Rep
  contributor:
    fullname: Grenet
– volume: 3
  year: 2018
  ident: bib4
  article-title: Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies
  publication-title: JCI Insight
  contributor:
    fullname: Clancy
– volume: 117
  start-page: 284
  year: 2014
  end-page: 288
  ident: bib24
  article-title: Lung arginase expression and activity is increased in cystic fibrosis mouse models
  publication-title: J Appl Physiol (1985)
  contributor:
    fullname: Grasemann
– volume: 292
  start-page: 1988
  year: 2017
  end-page: 1999
  ident: bib8
  article-title: Attenuation of phosphorylation-dependent activation of cystic fibrosis transmembrane conductance regulator (CFTR) by disease-causing mutations at the transmission interface
  publication-title: J Biol Chem
  contributor:
    fullname: Bear
– volume: 95
  start-page: 1005
  year: 1998
  end-page: 1015
  ident: bib30
  article-title: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
  publication-title: Cell
  contributor:
    fullname: Boucher
– volume: 155
  start-page: 252
  year: 2016
  end-page: 256
  ident: bib7
  article-title: A low-cost method of ciliary beat frequency measurement using iPhone and MATLAB: rabbit study
  publication-title: Otolaryngol Head Neck Surg
  contributor:
    fullname: Wong
– volume: 13
  start-page: 114
  year: 1999
  end-page: 118
  ident: bib17
  article-title: Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome
  publication-title: Eur Respir J
  contributor:
    fullname: Ratjen
– volume: 110
  start-page: 4404
  year: 2013
  end-page: 4409
  ident: bib25
  article-title: Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Hwang
– volume: 106
  start-page: 18825
  year: 2009
  end-page: 18830
  ident: bib45
  article-title: Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Hazlewood
– volume: 163
  start-page: 317
  year: 2013
  end-page: 319
  ident: bib20
  article-title: Arginine metabolism in patients with cystic fibrosis
  publication-title: J Pediatr
  contributor:
    fullname: Pencharz
– volume: 303
  start-page: C1173
  year: 2012
  end-page: C1179
  ident: bib10
  article-title: Development of primary human nasal epithelial cell cultures for the study of cystic fibrosis pathophysiology
  publication-title: Am J Physiol Cell Physiol
  contributor:
    fullname: Ennis
– volume: 25
  start-page: 62
  year: 2005
  end-page: 68
  ident: bib18
  article-title: Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study
  publication-title: Eur Respir J
  contributor:
    fullname: Ratjen
– volume: 12
  start-page: 468
  year: 2013
  end-page: 474
  ident: bib23
  article-title: A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis
  publication-title: J Cyst Fibros
  contributor:
    fullname: Ratjen
– volume: 197
  start-page: A5806
  year: 2018
  ident: bib44
  article-title: The in vitro and ex vivo efficacy of novel arginase inhibitors for the treatment of allergic asthma
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: Meurs
– volume: 2
  start-page: 12
  year: 2017
  ident: bib1
  article-title: Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
  publication-title: NPJ Genom Med
  contributor:
    fullname: Ouyang
– volume: 275
  start-page: L917
  year: 1998
  end-page: L923
  ident: bib14
  article-title: An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells
  publication-title: Am J Physiol
  contributor:
    fullname: Varesio
– volume: 5
  start-page: 557
  year: 2017
  end-page: 567
  ident: bib37
  article-title: Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
  publication-title: Lancet Respir Med
  contributor:
    fullname: Davies
– volume: 172
  start-page: 1523
  year: 2005
  end-page: 1528
  ident: bib22
  article-title: Increased arginase activity in cystic fibrosis airways
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: Ratjen
– volume: 5
  start-page: 101
  year: 2017
  ident: bib40
  article-title: Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
  publication-title: J Immunother Cancer
  contributor:
    fullname: Marguier
– volume: 18
  start-page: 726
  year: 2012
  end-page: 736
  ident: bib21
  article-title: Nitric oxide and L-arginine deficiency in cystic fibrosis
  publication-title: Curr Pharm Des
  contributor:
    fullname: Ratjen
– volume: 20
  start-page: 1204
  year: 2015
  end-page: 1217
  ident: bib31
  article-title: Facilitating structure-function studies of CFTR modulator sites with efficiencies in mutagenesis and functional screening
  publication-title: J Biomol Screen
  contributor:
    fullname: Bear
– volume: 126
  start-page: 32
  year: 2004
  end-page: 41
  ident: bib29
  article-title: The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon
  publication-title: Gastroenterology
  contributor:
    fullname: Boucher
– volume: 13
  start-page: 29
  year: 2014
  end-page: 36
  ident: bib47
  article-title: Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
  publication-title: J Cyst Fibros
  contributor:
    fullname: Hoffman
– volume: 31
  start-page: 815
  year: 2008
  end-page: 821
  ident: bib16
  article-title: Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients
  publication-title: Eur Respir J
  contributor:
    fullname: Grasemann
– volume: 9
  start-page: 719
  year: 2018
  ident: bib27
  article-title: Molecular mechanism of action of trimethylangelicin derivatives as CFTR modulators
  publication-title: Front Pharmacol
  contributor:
    fullname: Chilin
– volume: 510
  start-page: 93
  year: 2011
  end-page: 100
  ident: bib49
  article-title: Regulation of ciliary motility: conserved protein kinases and phosphatases are targeted and anchored in the ciliary axoneme
  publication-title: Arch Biochem Biophys
  contributor:
    fullname: Sale
– volume: 84
  start-page: 303
  year: 1990
  end-page: 312
  ident: bib12
  article-title: Culture and comparison of human bronchial and nasal epithelial cells in vitro
  publication-title: Respir Med
  contributor:
    fullname: Davies
– volume: 29
  start-page: 643
  year: 2018
  end-page: 652
  ident: bib5
  article-title: Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy
  publication-title: Hum Gene Ther
  contributor:
    fullname: Coates
– volume: 14
  start-page: 151
  year: 2016
  end-page: 155
  ident: bib26
  article-title: Dietary nitrate acutely and markedly increased exhaled nitric oxide in a cystic fibrosis case
  publication-title: Clin Med Res
  contributor:
    fullname: Elnazir
– volume: 93
  start-page: 612
  year: 2018
  end-page: 618
  ident: bib28
  article-title: Correctors of the major cystic fibrosis mutant interact through membrane-spanning domains
  publication-title: Mol Pharmacol
  contributor:
    fullname: Bear
– volume: 52
  start-page: 229
  year: 2016
  end-page: 237
  ident: bib51
  article-title: Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR
  publication-title: Drugs Today (Barc)
  contributor:
    fullname: Naren
– volume: 373
  start-page: 220
  year: 2015
  end-page: 231
  ident: bib48
  article-title: Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR
  publication-title: N Engl J Med
  contributor:
    fullname: Flume
– volume: 66
  start-page: 984
  year: 2011
  ident: bib38
  article-title: VX-770, a CFTR potentiator, may have a potential clinical benefit in a subgroup of people with cystic fibrosis
  publication-title: Thorax
  contributor:
    fullname: Shah
– year: 2013
  ident: bib33
  article-title: Culturing of human nasal epithelial cells at the air liquid interface
  publication-title: J Vis Exp
  contributor:
    fullname: Jaspers
– volume: 162
  start-page: 2172
  year: 2000
  end-page: 2176
  ident: bib19
  article-title: Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: Ratjen
– volume: 283
  start-page: 25103
  year: 2008
  ident: bib43
  article-title: Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site
  publication-title: J Biol Chem
  contributor:
    fullname: Kunzelmann
– volume: 7
  year: 2018
  ident: bib2
  article-title: SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion
  publication-title: eLife
  contributor:
    fullname: Bear
– volume: 104
  start-page: 15370
  year: 2007
  end-page: 15375
  ident: bib34
  article-title: Processing and function of CFTR-DeltaF508 are species-dependent
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Welsh
– volume: 1
  start-page: 235
  year: 2016
  end-page: 243
  ident: bib9
  article-title: Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
  publication-title: Expert Rev Precis Med Drug Dev
  contributor:
    fullname: Gentzsch
– volume: 51
  start-page: S23
  year: 2016
  end-page: S34
  ident: bib3
  article-title: Individualized medicine using intestinal responses to CFTR potentiators and correctors
  publication-title: Pediatr Pulmonol
  contributor:
    fullname: Beekman
– volume: 8
  year: 2016
  ident: bib11
  article-title: Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
  publication-title: Sci Transl Med
  contributor:
    fullname: Houwen
– volume: 14
  start-page: 228
  year: 2015
  end-page: 236
  ident: bib42
  article-title: Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease
  publication-title: J Cyst Fibros
  contributor:
    fullname: Saavedra
– volume: 93
  start-page: 579
  year: 1999
  end-page: 583
  ident: bib36
  article-title: Effect of inhaled nitric oxide on pulmonary function in cystic fibrosis
  publication-title: Respir Med
  contributor:
    fullname: Grasemann
– volume: 108
  start-page: 18843
  year: 2011
  end-page: 18848
  ident: bib46
  article-title: Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Olson
– volume: 560
  start-page: 519
  year: 2004
  end-page: 532
  ident: bib41
  article-title: Regulation of human airway ciliary beat frequency by intracellular pH
  publication-title: J Physiol
  contributor:
    fullname: Salathe
– volume: 86
  start-page: 833
  year: 2018
  end-page: 843
  ident: bib32
  article-title: Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site
  publication-title: Proteins
  contributor:
    fullname: Windemuth
– volume: 287
  start-page: 36639
  year: 2012
  end-page: 36649
  ident: bib13
  article-title: Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner
  publication-title: J Biol Chem
  contributor:
    fullname: Bear
– ident: 2019091712290063000_96.4.515.35
  doi: 10.1038/s41598-017-07504-1
– ident: 2019091712290063000_96.4.515.46
  doi: 10.1073/pnas.1105787108
– ident: 2019091712290063000_96.4.515.47
  doi: 10.1016/j.jcf.2013.06.008
– volume: 7
  start-page: e37963
  year: 2018
  ident: 2019091712290063000_96.4.515.2
  article-title: SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion
  publication-title: eLife
  doi: 10.7554/eLife.37963
  contributor:
    fullname: Ahmadi
– ident: 2019091712290063000_96.4.515.28
  doi: 10.1124/mol.118.111799
– ident: 2019091712290063000_96.4.515.38
  doi: 10.1136/thx.2011.159491
– ident: 2019091712290063000_96.4.515.22
  doi: 10.1164/rccm.200502-253OC
– ident: 2019091712290063000_96.4.515.19
  doi: 10.1164/ajrccm.162.6.2003106
– ident: 2019091712290063000_96.4.515.7
  doi: 10.1177/0194599816640219
– volume: 3
  start-page: e99385
  issue: 13
  year: 2018
  ident: 2019091712290063000_96.4.515.4
  article-title: Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.99385
  contributor:
    fullname: Brewington
– ident: 2019091712290063000_96.4.515.41
  doi: 10.1113/jphysiol.2004.068171
– ident: 2019091712290063000_96.4.515.25
  doi: 10.1073/pnas.1215982110
– ident: 2019091712290063000_96.4.515.29
  doi: 10.1053/j.gastro.2003.10.049
– ident: 2019091712290063000_96.4.515.21
  doi: 10.2174/138161212799315911
– ident: 2019091712290063000_96.4.515.45
  doi: 10.1073/pnas.0904709106
– volume: 2
  start-page: 12
  year: 2017
  ident: 2019091712290063000_96.4.515.1
  article-title: Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
  publication-title: NPJ Genom Med
  doi: 10.1038/s41525-017-0015-6
  contributor:
    fullname: Ahmadi
– ident: 2019091712290063000_96.4.515.31
  doi: 10.1177/1087057115605834
– ident: 2019091712290063000_96.4.515.18
  doi: 10.1183/09031936.04.00086104
– ident: 2019091712290063000_96.4.515.49
  doi: 10.1016/j.abb.2011.04.003
– ident: 2019091712290063000_96.4.515.34
  doi: 10.1073/pnas.0706974104
– ident: 2019091712290063000_96.4.515.48
  doi: 10.1056/NEJMoa1409547
– volume: 163
  start-page: 317
  year: 2013
  ident: 2019091712290063000_96.4.515.20
  article-title: Arginine metabolism in patients with cystic fibrosis
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2013.02.042
  contributor:
    fullname: Grasemann
– volume: 29
  start-page: 643
  year: 2018
  ident: 2019091712290063000_96.4.515.5
  article-title: Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy
  publication-title: Hum Gene Ther
  doi: 10.1089/hum.2017.201
  contributor:
    fullname: Cao
– ident: 2019091712290063000_96.4.515.24
  doi: 10.1152/japplphysiol.00167.2014
– volume: 9
  start-page: 719
  year: 2018
  ident: 2019091712290063000_96.4.515.27
  article-title: Molecular mechanism of action of trimethylangelicin derivatives as CFTR modulators
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2018.00719
  contributor:
    fullname: Laselva
– ident: 2019091712290063000_96.4.515.11
  doi: 10.1126/scitranslmed.aad8278
– ident: 2019091712290063000_96.4.515.16
  doi: 10.1183/09031936.00103907
– ident: 2019091712290063000_96.4.515.26
  doi: 10.3121/cmr.2016.1320
– ident: 2019091712290063000_96.4.515.39
  doi: 10.1164/ajrccm.165.7.2105032
– volume: 51
  start-page: S23
  year: 2016
  ident: 2019091712290063000_96.4.515.3
  article-title: Individualized medicine using intestinal responses to CFTR potentiators and correctors
  publication-title: Pediatr Pulmonol
  doi: 10.1002/ppul.23553
  contributor:
    fullname: Beekman
– ident: 2019091712290063000_96.4.515.13
  doi: 10.1074/jbc.M112.393637
– ident: 2019091712290063000_96.4.515.15
  doi: 10.1183/13993003.congress-2018.PA3415
– ident: 2019091712290063000_96.4.515.40
  doi: 10.1186/s40425-017-0308-4
– volume: 52
  start-page: 229
  year: 2016
  ident: 2019091712290063000_96.4.515.51
  article-title: Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR
  publication-title: Drugs Today (Barc)
  doi: 10.1358/dot.2016.52.4.2467205
  contributor:
    fullname: Zhang
– ident: 2019091712290063000_96.4.515.10
  doi: 10.1152/ajpcell.00384.2011
– volume: 197
  start-page: A5806
  year: 2018
  ident: 2019091712290063000_96.4.515.44
  article-title: The in vitro and ex vivo efficacy of novel arginase inhibitors for the treatment of allergic asthma
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: van den Berg
– ident: 2019091712290063000_96.4.515.8
  doi: 10.1074/jbc.M116.762633
– ident: 2019091712290063000_96.4.515.23
  doi: 10.1016/j.jcf.2012.12.008
– ident: 2019091712290063000_96.4.515.42
  doi: 10.1016/j.jcf.2014.10.006
– ident: 2019091712290063000_96.4.515.17
  doi: 10.1183/09031936.99.13111499
– ident: 2019091712290063000_96.4.515.30
  doi: 10.1016/S0092-8674(00)81724-9
– ident: 2019091712290063000_96.4.515.33
  doi: 10.3791/50646.
– volume: 5
  start-page: 557
  year: 2017
  ident: 2019091712290063000_96.4.515.37
  article-title: Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(17)30215-1
  contributor:
    fullname: Ratjen
– ident: 2019091712290063000_96.4.515.36
  doi: 10.1016/S0954-6111(99)90158-0
– ident: 2019091712290063000_96.4.515.9
  doi: 10.1080/23808993.2016.1175299
– volume: 2
  start-page: 15034
  year: 2015
  ident: 2019091712290063000_96.4.515.6
  article-title: Testing gene therapy vectors in human primary nasal epithelial cultures
  publication-title: Mol Ther Methods Clin Dev
  doi: 10.1038/mtm.2015.34
  contributor:
    fullname: Cao
– ident: 2019091712290063000_96.4.515.12
  doi: 10.1016/S0954-6111(08)80058-3
– volume: 86
  start-page: 833
  year: 2018
  ident: 2019091712290063000_96.4.515.32
  article-title: Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site
  publication-title: Proteins
  doi: 10.1002/prot.25496
  contributor:
    fullname: Molinski
– ident: 2019091712290063000_96.4.515.50
  doi: 10.1016/j.jcf.2011.12.005
– volume: 275
  start-page: L917
  year: 1998
  ident: 2019091712290063000_96.4.515.14
  article-title: An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells
  publication-title: Am J Physiol
  contributor:
    fullname: Galietta
– volume: 283
  start-page: 25103
  year: 2008
  ident: 2019091712290063000_96.4.515.43
  article-title: Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)49254-5
  contributor:
    fullname: Treharne
SSID ssj0014580
Score 2.5161254
Snippet ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing and anion channel activity...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 515
SubjectTerms Aminophenols - pharmacology
Aminopyridines - pharmacology
Animals
Arginase - antagonists & inhibitors
Arginine - metabolism
Benzodioxoles - pharmacology
Bronchi - cytology
Bronchi - drug effects
Bronchi - metabolism
Cells, Cultured
Cystic Fibrosis - drug therapy
Cystic Fibrosis - genetics
Cystic Fibrosis - metabolism
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Cytosol - metabolism
Drug Combinations
Humans
Intestinal Mucosa - metabolism
Mice
Mutation
Nitric Oxide - metabolism
Nose - cytology
Nose - drug effects
Quinolones - pharmacology
Title ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel
URI https://dx.doi.org/10.1124/mol.119.117143
https://www.ncbi.nlm.nih.gov/pubmed/31427400
https://search.proquest.com/docview/2292996248
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Za9tAEIC3iQslL6V33YsplPTBViutVpb16IakcVonxkkgb0LH2hbEkrEtWvfXd_aSlaSGthiEkJBX0nzamd2dg5APDrUTzoLU4qg-LRZRzwrQzLXQ1OeJM6bc5SI4eXDaOb5kJ1fe1c5uo-a1VK7iT8mvP8aV_I9U8RjKVUTJ_oNkqz_FA7iP8sUtShi3fyXjs9G33uBL3xrIehtcRBouk1LOAgxK7Omy60w4xR2I0hAyNECE-K1FZubWEQ6TC5GMZKjTTYxqa-4qzyZftvrL1mE-VU4CaKf2FhNRTwIt1fkqUl498hBqQuxoplks_b-MQ-hQefopg_Q0E6UAWmc_s5S3zrOJsP9FoJayfG_flNSgMz7DoXwu6urlIiutfIIRn4iCY8VCxkXk2uHflKQytX5b801G7s2aQSn1TWmdT7nW18J1KNMz5ifYVOUD1JvOojRTU-bYe1duKN_5j1pYkHLRrmZNnKDyv0Olp3t6KuZRdE-vVYEqrquRZ7V-3VMxp3f1DWUIyay4xt1ALIA7KulUDb75TNLnOoz6zLY3erfyhjSndsl9kc5RVID4elU5KjnM69o63Sg29_lmY3vkgbl8m2W1beQkLaiLR-ShHvpAT3H8mOzw_AnZHypJrdtwsQkFXLZhH4Y1GT69R27DDgp2KMZQgx0q2CHLQXEFhivQsEMNdjCwQ38JBnaI12BgBwV7GwzqsEG9DUgBVKCLe1GggwQdKtBhVQCCfueGboAONdChAh006M_I5dHhxcGxpcuXWAnz7JXldhIPBwA-akzbpVHaZV7qjO3UTfyxMAKZ4_PITdIoZZR34oQlvMOpm7g-_jw_cZ-TRl7k_CWBwIs6PhvbAY1T5rpo43dTHsc0CjhNu27cJB-N6MO5epOhHN1TFiIvuBOEipcmcQwZobaxle0cItJbr3lvEApR-YgVRXwnRbkMKcXRVdChrNskLxRbVfsGy1dbz7wme5tP8w1prBYlf4sm_ip-J7-A3za3BN4
link.rule.ids 314,780,784,27924,27925
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ORKAMBI-Mediated+Rescue+of+Mucociliary+Clearance+in+Cystic+Fibrosis+Primary+Respiratory+Cultures+Is+Enhanced+by+Arginine+Uptake%2C+Arginase+Inhibition%2C+and+Promotion+of+Nitric+Oxide+Signaling+to+the+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Channel&rft.jtitle=Molecular+pharmacology&rft.au=Wu%2C+Yu-Sheng&rft.au=Jiang%2C+Janet&rft.au=Ahmadi%2C+Saumel&rft.au=Lew%2C+Alexandria&rft.date=2019-10-01&rft.eissn=1521-0111&rft.volume=96&rft.issue=4&rft.spage=515&rft_id=info:doi/10.1124%2Fmol.119.117143&rft_id=info%3Apmid%2F31427400&rft.externalDocID=31427400
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon